Oncobiologics Teams Up With InVentiv On Biosimilar Development
This article was originally published in The Pink Sheet Daily
The New Jersey biotech has found ways to cut costs of clinical trials by sharing the risk/reward with partners in hopes of bringing a slate of biosimlars to market beginning in early 2017.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.